Clinical trials: Diffuse Parenchymal Lung Diseases
Pulmonary Sarcoidosis
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment.
- Trial name
- NCT05415137
- Testing
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg
- Where
- 91 sites in United States, Brazil and 7 more
- Volunteers
- 268 people
- Sponsor
- aTyr Pharma, Inc.
Lung Diseases, Interstitial
A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease
The main objectives of this imaging biomarker study are to assess the annual lung function change in patients with progressive fibrosing interstitial lung disease (PF-ILD) including idiopathic pulmonary fibrosis (IPF), with Usual…
- Trial name
- NCT05492994
- Testing
- Spirometry, Diffusing Capacity of the Lung for Carbon Monoxide (DLCO), Magnetic Resonance Imaging
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Kidney Failure, Chronic, Transplantation
Fibrosis in Renal Allografts
This prospective, randomized study, comparing sirolimus to cyclosporine in renal transplant recipients, has two major objectives: 1.
- Conditions
- Kidney Failure, Chronic, Transplantation, Immunosuppression, Interstitial Fibrosis
- Trial name
- NCT00493194
- Testing
- sirolimus, cyclosporine, daclizumab
- Where
- 3 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Antwerp
Acute Exacerbation of COPD, Acute Exacerbation of Bronchiectasis
Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in…
- Conditions
- Acute Exacerbation of COPD, Acute Exacerbation of Bronchiectasis, Acute Exacerbation of Asthma, Interstitial Lung Disease
- Trial name
- DVD (NCT04098094)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Respiratory Tract Diseases
Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion
Only about 15% of the potential candidates for lung donation are considered suitable for transplantation. A new method for ex vivo lung perfusion (EVLP) has been developed and can be used for evaluation and reconditioning of…
- Trial name
- NCT01353105
- Testing
- Ex vivo lung transplantation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- InCor Heart Institute
Non Small Cell Lung Cancer (NSCLC)
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
Stereotactic body radiotherapy (SBRT) has emerged as one of the leading curative method for early stage non-small cell lung cancer (NSCLC).
- Trial name
- SBRT FLT-PET (NCT02456246)
- Testing
- FLT-PET
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- University Health Network, Toronto
Sjogren's Syndrome, Interstitial Lung Disease
Sjogren's Lung Study
Lung involvement in Sjögren's syndrome is common and causes reduced quality of life and increased mortality. Sjögren's syndrome-related lung diseases (SS-RLD) are classified and treated as the primary lung diseases they resemble.
- Conditions
- Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis
- Trial name
- NCT04843345
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Stanford University
Systemic Sclerosis, Scleroderma
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients.
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease
- Trial name
- MYILD (NCT02896205)
- Testing
- Mycophenolate mofetil
- Where
- India
- Volunteers
- 41 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Interstitial Lung Disease
Comparison of Upper and Lower Limb Maximal Exercise Capacities and Muscle Oxygenation in Patients With ILD
Interstitial lung diseases (ILD) are a complex group of diseases that cause significant morbidity and mortality, develop diffuse lung parenchyma and alveolar inflammation, as well as interstitial fibrosis, which refers to more…
- Trial name
- NCT06141603
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Gazi University
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Pulmonary Hypertension, Interstitial Lung Disease
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with…
- Trial name
- NCT05649722
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 22 sites in Argentina, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Insmed Incorporated
Langerhans Cell Histiocytosis (LCH)
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues.
- Trial name
- NCT07431060
- Testing
- Prednisone, Vincristine, Mercaptopurine
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Histiocytosis
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis resistant to conventional therapy and without the…
- Trial name
- TRAM (NCT04943224)
- Testing
- Trametinib
- Where
- Poland
- Volunteers
- 12 people
- Sponsor
- Anna Raciborska
Idiopathic Pulmonary Fibrosis
Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes
Two oral medications, nintedanib and pirfenidone, were approved simultaneously by the FDA in October 2014 for the treatment of this disease.
- Trial name
- IPF-LTOS (NCT04316780)
- Testing
- Retrospective observational study- no intervention to occur.
- Where
- 8 sites in United States
- Volunteers
- 320 people
- Sponsor
- Steward St. Elizabeth's Medical Center of Boston, Inc.
Idiopathic Pulmonary Fibrosis
68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis
The investigators aim to evaluate the role of 68Ga-DOTA-NOC PET/CT in patients with idiopathic pulmonary fibrosis, in particular in patients with a diagnosis of IPF/UIP (idiopathic pulmonary fibrosis, diagnosed based in the…
- Trial name
- NCT01321996
- Testing
- 68Ga-DOTA-NOC PET/CT
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Fibrosis, Pulmonary
Inspiratory Effort Assessed Through Nasal Pressure Measurement in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a fibrosing progressive interstitial lung disease with unknown etiology, with a median survival of 3 years since first diagnosis.
- Trial name
- NASA (NCT05310669)
- Testing
- Nasal pressure assessment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Modena and Reggio Emilia
Idiopathic Pulmonary Fibrosis
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT04312594
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Myositis, Interstitial Lung Disease
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
- Trial name
- ATtackMy-ILD (NCT03215927)
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Rohit Aggarwal, MD
Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic
BPF Genetics of ILD Study
The investigators aim to examine the genetic determinants of interstitial lung disease in a cohort of subjects with regular exposure to pigeons, a known cause of one form of interstitial lung disease known as hypersensitivity…
- Conditions
- Lung; Disease, Interstitial, With Fibrosis, Alveolitis, Extrinsic Allergic, Bird Fancier's Lung, Idiopathic Interstitial Pneumonias
- Trial name
- BPF GILD (NCT03747627)
- Testing
- Genetic profiling
- Where
- 2 sites in United Kingdom
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- University of Dundee
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.